Efficacy of Pulmozyme ® on Arterial Recanalization in Post-thrombectomy Patients Managed for Ischemic Stroke (NETs-target)
Condition:   Ischemic Stroke Intervention:   Drug: Administration of dornase alfa Sponsor:   Fondation Ophtalmologique Adolphe de Rothschild Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 5, 2021 Category: Research Source Type: clinical trials

Phase 2 Trial Using rhDNase to Reduce Mortality in COVID-19 Patients With Respiratory Failure
Condition:   Covid19 Intervention:   Drug: Pulmozyme/ Recombinant human deoxyribonuclease (rh-DNase) Sponsors:   Jon Simmons;   University of South Alabama Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 24, 2020 Category: Research Source Type: clinical trials

Phase 2 Trial Using rhDNase to Reduce Mortality in COVID-19 Patients With Respiratory Failure
Condition:   Covid19 Interventions:   Drug: Pulmozyme/ Recombinant human deoxyribonuclease (rh-DNase);   Drug: 0.9%sodium chloride Sponsors:   Jon Simmons;   University of South Alabama Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 24, 2020 Category: Research Source Type: clinical trials

Phase 2 Trial Using rhDNase to Reduce Mortality in COVID-19 Patients With Respiratory Failure
Condition:   Covid19 Intervention:   Drug: Pulmozyme/ Recombinant human deoxyribonuclease (rh-DNase) Sponsors:   Jon Simmons;   University of South Alabama Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 24, 2020 Category: Research Source Type: clinical trials

Efficacy and safety of aerosolized intra-tracheal dornase alfa administration in patients with SARS-CoV-2-induced acute respiratory distress syndrome (ARDS): a structured summary of a study protocol for a randomised controlled trial
AbstractObjectivesSevere Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) may trigger severe pneumonia in coronavirus disease of 2019 (COVID-19) patients through release of damage-associated molecular patterns (DAMPs) and recruitment of neutrophils in the lungs. Activated neutrophils induce inflammation and severe alveolar injury by releasing neutrophil extracellular traps (NETs). The backbones of many DAMPs and NETs are made of extracellular, cell-free DNA decorated with highly toxic compounds such as elastase, myeloperoxidase and citrullinated histones. Dornase alfa is a FDA-approved recombinant human DNAse 1 for th...
Source: Trials - June 18, 2020 Category: Research Source Type: clinical trials

Dornase Alpha for the Treatment of COVID-19
Condition:   COVID-19 Intervention:   Drug: Pulmozyme Sponsors:   Acibadem University;   The Scientific and Technological Research Council of Turkey Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 16, 2020 Category: Research Source Type: clinical trials

Dornase Alfa for ARDS in Patients With SARS-CoV-2
Conditions:   SARS-CoV 2;   ARDS Intervention:   Drug: Dornase Alfa Inhalation Solution Sponsor:   University of Missouri-Columbia Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 27, 2020 Category: Research Source Type: clinical trials

Pulmozyme to Improve COVID-19 ARDS Outcomes
Condition:   COVID Interventions:   Drug: Pulmozyme;   Drug: Placebo Sponsors:   Boston Children’s Hospital;   Brigham and Women's Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 27, 2020 Category: Research Source Type: clinical trials

Dornase Alfa for ARDS in Patients With SARS-CoV-2
Conditions:   SARS-CoV 2;   ARDS Intervention:   Drug: Dornase Alfa Inhalation Solution Sponsor:   University of Missouri-Columbia Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 27, 2020 Category: Research Source Type: clinical trials

Pulmozyme to Improve COVID-19 ARDS Outcomes
Condition:   COVID Interventions:   Drug: Pulmozyme;   Drug: Placebo Sponsors:   Boston Children’s Hospital;   Brigham and Women's Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 27, 2020 Category: Research Source Type: clinical trials

Dornase Alfa for ARDS in Patients With SARS-CoV-2
Conditions:   SARS-CoV 2;   ARDS Intervention:   Drug: Dornase Alfa Inhalation Solution Sponsor:   University of Missouri-Columbia Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 27, 2020 Category: Research Source Type: clinical trials

Pulmozyme to Improve COVID-19 ARDS Outcomes
Condition:   COVID Interventions:   Drug: Pulmozyme;   Drug: Placebo Sponsors:   Boston Children’s Hospital;   Brigham and Women's Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 27, 2020 Category: Research Source Type: clinical trials

Dornase Alfa for ARDS in Patients With SARS-CoV-2
Conditions:   SARS-CoV 2;   ARDS Intervention:   Drug: Dornase Alfa Inhalation Solution Sponsor:   University of Missouri-Columbia Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 27, 2020 Category: Research Source Type: clinical trials

Pulmozyme to Improve COVID-19 ARDS Outcomes
Condition:   COVID Interventions:   Drug: Pulmozyme;   Drug: Placebo Sponsors:   Boston Children’s Hospital;   Brigham and Women's Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 27, 2020 Category: Research Source Type: clinical trials

Dornase Alfa for ARDS in Patients With SARS-CoV-2
Conditions:   SARS-CoV 2;   ARDS Intervention:   Drug: Dornase Alfa Inhalation Solution Sponsor:   University of Missouri-Columbia Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 27, 2020 Category: Research Source Type: clinical trials

Pulmozyme to Improve COVID-19 ARDS Outcomes
Condition:   COVID Interventions:   Drug: Pulmozyme;   Drug: Placebo Sponsors:   Boston Children’s Hospital;   Brigham and Women's Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 27, 2020 Category: Research Source Type: clinical trials

Dornase Alfa for ARDS in Patients With SARS-CoV-2
Conditions:   SARS-CoV 2;   ARDS Intervention:   Drug: Dornase Alfa Inhalation Solution Sponsor:   University of Missouri-Columbia Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 27, 2020 Category: Research Source Type: clinical trials

Pulmozyme to Improve COVID-19 ARDS Outcomes
Condition:   COVID Interventions:   Drug: Pulmozyme;   Drug: Placebo Sponsors:   Boston Children’s Hospital;   Brigham and Women's Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 27, 2020 Category: Research Source Type: clinical trials

Dornase Alfa for ARDS in Patients With SARS-CoV-2
Conditions:   SARS-CoV 2;   ARDS Intervention:   Drug: Dornase Alfa Inhalation Solution Sponsor:   University of Missouri-Columbia Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 27, 2020 Category: Research Source Type: clinical trials

Pulmozyme to Improve COVID-19 ARDS Outcomes
Condition:   COVID Interventions:   Drug: Pulmozyme;   Drug: Placebo Sponsors:   Boston Children’s Hospital;   Brigham and Women's Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 27, 2020 Category: Research Source Type: clinical trials

Dornase Alfa for ARDS in Patients With SARS-CoV-2
Conditions:   SARS-CoV 2;   ARDS Intervention:   Drug: Dornase Alfa Inhalation Solution Sponsor:   University of Missouri-Columbia Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 27, 2020 Category: Research Source Type: clinical trials

Pulmozyme to Improve COVID-19 ARDS Outcomes
Condition:   COVID Interventions:   Drug: Pulmozyme;   Drug: Placebo Sponsors:   Boston Children’s Hospital;   Brigham and Women's Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 27, 2020 Category: Research Source Type: clinical trials

Dornase Alfa Administered to Patients With COVID-19 (DACOVID)
Conditions:   COVID-19;   Mechanical Ventilation Intervention:   Drug: Dornase Alfa Sponsors:   Feinstein Institute for Medical Research;   Cold Spring Harbor Laboratory Active, not recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 14, 2020 Category: Research Source Type: clinical trials